Development and Validation of the Brief Support Group Leader Self‐Efficacy Scale Among Scleroderma Peer Support Group Leaders
ACR Open Rheumatology · 2026-04 · 8 (4)
DOI: 10.1002/acr2.90027 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACR Open Rheumatology, online erschienen am 06.04.2026. Verfasst von Sabrina Provencher und 8 weiteren Autor:innen. Beteiligte Einrichtung: Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CIHR, Canada Research Chairs, Fonds de recherche du Québec.
Abstract (Originalsprache)
Objective
Our objective was to develop a brief Support Group Leader Self‐efficacy Scale (Brief‐SGLSS) that maintains the core content and measurement properties of the full 32‐item SGLSS among systemic sclerosis (SSc) support group leaders.
Methods
Development and validation involved four steps conducted by researchers and a Support Group Advisory Team of people with SSc: (1) item content assessment and prioritization, including a Delphi process; (2) item analysis and preliminary selection, including analysis of SGLSS measurement properties using Scleroderma Patient‐centered Intervention Network–Scleroderma‐Support group Leader Education (SPIN‐SSLED) trial data and a data‐driven item resampling process; (3) advisory team input to select final Brief‐SGLSS items; and (4) comparison of convergent validity and trial change data of the Brief‐SGLSS and full SGLSS.
Results
Items were categorized into six content themes. Two Delphi rounds resulted in one item excluded from consideration. A 6‐item Brief‐SGLSS was selected at the consensus advisory panel meeting based on the resampling process and content and statistical considerations. The Pearson correlation of the Brief‐SGLSS and full SGLSS was 0.96. The standardized mean difference between intervention (n = 74) and waitlist (n = 72) groups in the SPIN‐SSLED trial immediately post intervention was 0.93 (95% confidence interval [CI] 0.59–1.27) for the full 32‐item SGLSS and 0.93 (95% CI 0.58–1.27) for the Brief‐SGLSS. Convergent validity of the Brief‐SGLSS and full SGLSS with other measures was similar.
Conclusion
The 6‐item SGLSS is shorter and more feasibly implemented than the full SGLSS and maintains similar measurement properties.
Autor:innen und Institutionen
- Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada.
- Department of Psychiatry, McGill University, Montreal, Quebec, Canada.
- Department of Applied Statistics, Social Science, and the Humanities, New York University, New York, New York.
- National Scleroderma Foundation, Michigan Chapter, Southfield, Michigan.
- Sclérodermie Québec, Sherbrooke, Quebec, Canada.
- Department of Medicine, McGill University, Montreal, Quebec, Canada.
ORCID-Profile: Daphna Harel, Marie Hudson, Brett D Thombs
Förderung
- CIHR
- Canada Research Chairs
- Fonds de recherche du Québec
- Canadian Institutes of Health Research
Zitieren
APA
Provencher, S., Harel, D., Henry, R. S., Carrier, M. E., Dyas, L., Konrad, V., Hudson, M., Thombs, B. D., & SPIN‐SSLED Support Group Advisory Team (2026). Development and Validation of the Brief Support Group Leader Self‐Efficacy Scale Among Scleroderma Peer Support Group Leaders. ACR Open Rheumatology, 8(4). https://doi.org/10.1002/acr2.90027
Vancouver
Provencher S, Harel D, Henry RS, Carrier ME, Dyas L, Konrad V, et al. Development and Validation of the Brief Support Group Leader Self‐Efficacy Scale Among Scleroderma Peer Support Group Leaders. ACR Open Rheumatology. 2026;8(4). doi:10.1002/acr2.90027
BibTeX
@article{Provencher2026,
author = {Provencher, Sabrina and Harel, Daphna and Henry, Richard S and Carrier, Marie-Eve and Dyas, Laura and Konrad, Violet and Hudson, Marie and Thombs, Brett D and SPIN‐SSLED Support Group Advisory Team, SPIN‐SSLED Support Group Advisory Team},
title = {Development and Validation of the Brief Support Group Leader Self‐Efficacy Scale Among Scleroderma Peer Support Group Leaders},
journal = {ACR Open Rheumatology},
year = {2026},
volume = {8},
number = {4},
doi = {10.1002/acr2.90027}
}
EUVIMED